u38_startu38_endu38_line
u61_startu61_endu61_line

 

 

Intro

u91_startu91_endu91_line

 

Results

u96_startu96_endu96_line

 

Nighttime

Routine

u101_startu101_endu101_line

 

Tips for Success

u106_startu106_endu106_line

 

Find a

Physician

u116_startu116_endu116_line

Safety Information

 

 

 

Intro

u131_startu131_endu131_line

 

Results

u136_startu136_endu136_line

 

Nighttime

Routine

u141_startu141_endu141_line

 

Tips for Success

u146_startu146_endu146_line

 

Find a

Physician

u156_startu156_endu156_line

Safety Information

 

 

 

 

 

u177_startu177_endu177_line

The #1 Prescribed Brand

for Fine Facial Wrinkles1

The lightweight, elegant, nongreasy formulation of Renova®
(tretinoin cream) 0.02% is backed by 20 years of clinical research and results, and is specially formulated to reduce the appearance of fine facial wrinkles, improving the overall appearance and feel of your skin.2,3

As a topical tretinoin, Renova is believed to activate Vitamin A acid receptors below the skin’s surface.4

Available in a 20-g tube and a 44-g controlled-dose pump.Valid prescription required. RENOVA (trentinoin cream) 0.02% 40-g and 60-g tubes are also available, but must be purchased through a pharmacy.

RENOVA (tretinoin cream) 0.02% is a serious medication that may help treat but will not "cure" fine wrinkles, spotty skin discoloration, and rough feeling skin. RENOVA 0.02% WILL NOT REPAIR SKIN, ELIMINATE WRINKLES, OR REVERSE AGING.

RENOVA should be used as part of a broad skin care program that includes avoiding direct sunlight (by using protective clothing and sunscreens with a minimum SPF of 15) and using other moisturizing facial creams.

Visible Results

Patients experience improvements after 24 weeks using Renova® (tretinoin cream) 0.02% as part of a complete skin care program, including sun protection.*5

 

 

  • In a clinical trial, patients experienced improvements after 24 weeks4,6
    – The appearance of crow’s feet was reduced
  • The safety and effectiveness of using RENOVA daily for greater than 52 weeks have not been established2

* Study results for Renova 0.02% as part of a comprehensive skin care program, including sun protection.
Photos have not been retouched. Results may vary.

A Simple Nighttime Routine

  1. Wash face thoroughly with a mild Obagi® cleanser.
    Pat skin dry and wait 20 to 30 minutes before applying Renova®.
  2. If using a tube, squeeze a pearl-sized amount of Renova onto your fingertip. If using a pump, fully depress the pump 2 times.
  3. Dab onto your forehead, chin, and both cheeks.
  4. Spread the dabs out in each area so they form a thin layer that covers your entire face.
  5. Smooth into your skin until absorbed completely.

Use Renova (tretinoin cream) 0.02% as part of a daily skin care and sun avoidance regimen. Because everyone’s skin is different, it’s important to follow your physician’s instructions on how to use Renova.

For more information about Obagi products, visit Obagi.com.

Tips for Success

  • Keep out of the sunlight as much as possible and do not use sun lamps
  • Use a sunscreen with SPF 30 or higher every morning and wear protective clothing to shield the treated areas of your skin
  • You may feel a tingling sensation when applying Renova, which is normal and should subside
  • Using more than the recommended amount will NOT increase your results and may cause irritation
  • Use a mild cleanser or nonmedicated soap to wash your face
  • Avoid putting medicated, abrasive, or alcohol-containing products on your face; make sure your toner/astringent is alcohol free
  • Use an Obagi® moisturizer and sunscreen that are noncomedogenic, with SPF 30 or higher
  • Avoid waxing, bleaching, and chemical hair remover

For more information about Obagi products, visit Obagi.com.

Talk to your skin care physician to see if Renova is right for you.

Don’t have a physician? Find a physician at Obagi.com.

Indication

RENOVA® (tretinoin cream) 0.02% is a serious medication that may help treat but will not "cure" fine wrinkles, spotty skin discoloration, and rough feeling skin. RENOVA 0.02% will not repair skin, eliminate wrinkles, or reverse aging.

RENOVA should be used as part of a broad skin care program that includes avoiding direct sunlight (by using protective clothing and sunscreens with a minimum SPF of 15) and using other moisturizing facial creams.

Important Safety Information

Do not use RENOVA if you are pregnant or trying to become pregnant.

Tell your doctor about any other medications or skin creams you are using. RENOVA increases your sensitivity to sunlight and should not be used with other medications or skin care products that increase sensitivity to sunlight.

You should not use RENOVA if you are sunburned or highly sensitive to the sun, if you have eczema, or if your skin is irritated. Remember to limit your time in the sun, and always wear a sunscreen with SPF 15 or higher.

RENOVA has not been studied for daily use beyond 12 months.

RENOVA 0.02% is a skin irritant. Almost all patients experience one or more local skin reactions, including dryness, peeling, burning/stinging, redness

RENOVA 0.02% WILL NOT REPAIR SKIN, ELIMINATE WRINKLES, OR REVERSE AGING.

View Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


References:1. Wolters Kluwer Health, Source® PHAST data, July 2011–August 2012. 2. Kircik LH. Safety and efficacy evaluation of tretinoin cream 0.02% for the reduction of photodamage: a pilot study. J Drugs Dermatol. 2012;11(1):83-90. 3. Kircik LH. Clinical update: the clinical efficacy and safety of tretinoin for the treatment of aging skin. Skin & Allergy News. 2009;(suppl):1-4. 4. RENOVA [prescribing information]. Bridgewater, NJ: Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC; 2012. 5. Data on file. Valeant Pharmaceuticals. 6. Nyirady J, Bergfeld W, Ellis C, et al. Tretinoin cream 0.02% for the treatment of photodamaged facial skin: a review of 2 double-blind clinical studies. Cutis. 2001;68(2):135-142.